3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioblastoma
40
Brain Neoplasms
34
Melanoma
15
Glioma
13
Carcinoma, Non-Small-Cell Lung
9
Gliosarcoma
7
Neoplasms
6
Carcinoma, Renal Cell
6
Stomach Neoplasms
5
Ovarian Neoplasms
4
Meningioma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Astrocytoma
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Recurrence
3
Central Nervous System Neoplasms
3
Uveal Melanoma
2
Turcot syndrome
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasm Metastasis
2
Interventions
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Vincristine
1
Valproic Acid
1
Thiotepa
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Cisplatin
1
Busulfan
1
Bone Marrow Transplantation
1
Antibodies, Monoclonal
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
pembrolizumab
×
CNS
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled